April 21st 2024
During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Validated Biomarkers in Renal Cell Carcinoma: The Search Continues
August 16th 2023Several immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.
Read More
Updated Data Supports Use of Nivolumab + Cabozantinib in Advanced ccRCC
August 9th 2023In the first article of a 2-part series, Rana McKay, MD, goes through the updated data from the CheckMate 9ER trial that supports the continued use of the combination of nivolumab and cabozantinib for patients with metastatic clear cell renal cell carcinoma.
Read More
Niraparib Maintenance Improves Survival in BRCA Wild-Type Ovarian Cancer
August 1st 2023In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.
Read More
Physicians Discuss Optimal Dosing for Lenvatinib Plus Pembrolizumab in Advanced RCC
July 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Nizar M. Tannir, MD, discussed with participants their experiences with the combination of lenvatinib and pembrolizumab, including the dosing schedule of pembrolizumab and finding a tolerable dose of lenvatinib.
Read More
Campbell Reviews Treatment Options for Recurrent ccRCC
July 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Campbell, MD, MS, discussed guidelines and available therapies for a patient who requires second-line treatment and beyond for metastatic renal cell carcinoma.
Read More
Physicians Discuss Counseling on Immunotherapy Discontinuation in RCC
July 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Adjusting to New Therapies in Relapsed/Refractory RCC
July 3rd 2023At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.
Read More
Advances in the Treatment of Advanced Renal Cell Carcinoma
June 30th 2023In the fifth article of this series, Hans Hammers, MD, PhD, outlines established treatment paradigms and discusses clinical trial data and ongoing research that are informing the future treatment landscape of advanced renal cell carcinoma.
Read More
Integrating Tivozanib into Treatment of Advanced RCC
June 22nd 2023In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.
Read More
Physicians Debate Role of Metastatic Sites in Treating Favorable-Risk RCC
June 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth M. Wulff-Burchfield, MD, and participants discussed the choice of frontline options for a patient with favorable-risk clear cell renal cell carcinoma, and how liver or lung metastases affect the decision.
Read More